Navigation Links
TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration
Date:9/10/2008

- Multicenter study finds unique combination of micronutrients superior to current 'AREDS' standard of care; Results supported by new omega-3 study -

HOUSTON, Sept. 10 /PRNewswire/ -- A landmark study at five university-based research centers found that TOZAL(R), a patented combination of antioxidants and micronutrients, enabled patients with "dry" macular degeneration to improve their vision. Patients in the study's placebo arm, who received the "AREDS-type" nutritional formulation (the current standard of care), continued to lose their eyesight. Results of the TOZAL study are supported by a major new study, which shows that omega-3 acids cut the risk of developing "wet" macular degeneration.

"The TOZAL study demonstrates that treatment with this supplement can help patients with age-related vision loss," said lead investigator Francis E. Cangemi, M.D., a macular degeneration specialist affiliated with Vitreo-Retinal Associates of New Jersey.

At six months, 57 percent of those in the TOZAL treatment group improved an average of one-half eye-chart line of visual acuity, and 20 percent stayed the same. All patients in the placebo (AREDS-type nutritional supplement) arm lost visual acuity, with an average loss of 1.49 lines at the end of six months. The treatment group continued to show improvement over time, while most in the placebo group continued to lose visual acuity over time. The study was published in the February 2007 issue of BMC Ophthalmology, a peer-reviewed open-access medical journal.

Age-related macular degeneration is a progressive disorder associated with central vision loss and is the leading cause of visual impairment and blindness in people over age 60. More than 15 million Americans have macular degeneration, and an additional 50 million are at risk. Ninety percent of those with macular degeneration have the atrophic or "dry" form of the disease.

Although there is no cure for macular degeneration, the accept
'/>"/>

SOURCE Atlantic Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine technology :

1. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
2. Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged
3. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
4. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
5. Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
8. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Premier Micronutrient Launches Supplement for Hearing Health
11. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Post Your Comments:
*Name:
*Comment:
*Email: